Aim: Menopause is defined as the depletion of the ovarian follicular reserve followed by the cessation of menstrual cycles. It has been
reported that gonadal steroid hormones play an important role in bladder function in women. Changes in urine pattern including
overactive bladder, stress incontinence and recurrent urinary tract infections occur as a result of menopause. 1,1-dimethylbiguanide
hydrochloride, metformin, (MET) is an oral anti-diabetic drug used to reduce hepatic glucose production and peripheral insulin
resistance. Recent studies have revealed that MET has a protective effects in diabetes induced bladder dysfunction. The aim of this
study was to test the therapeutic potential of MET in detrusor contractile function of ovariectomized (OVX) female rats.
Material and Methods: Bilateral ovariectomy was performed to eliminate endogenous gonadal steroids secretion. Four groups are
designed with 8 animals in each group: Control, MET-administered control, OVX, and MET-administered OVX groups. MET (25 mg/
kg) was administered daily by oral gavage for 14 days. Contractile activity of isolated bladder muscle strips were evaluated in vitro organ
bath. The contractile responses of detrusor strips were determined using different doses of carbachol (10-8-10-2M) and purinergic
agonist ATP. The relaxation response of strips were determined by isoproterenol
Results: The contractile responses of detrusor muscle strips to carbachol at doses 10-5-10-2 M were decreased in the OVX group
compared to control and MET treated control groups. MET treatment partially reversed the reduction in OVX-induced contractile
responses at 10-2 and 10 -3 M carbachol doses. There were no statistically significant difference in relaxation response between the
experimental groups.
Conclusion: Our findings suggest that treatment with MET could be the new potential therapeutic agent against bladder dyfunction
in postmenopausal women. Further studies are needed for the therapeutic potential of MET in detrusor dysfunction induced by
menopause.